A Phase 3 interventional study of Obicetrapib 10 mg/Bempedoic Acid Placebo and Bempedoic Acid 180mg/Placebo Obicetrapib in Mixed Dyslipidemia and Hypercholesterolaemia, sponsored by A. Menarini International Licensing S.A.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by A. Menarini International Licensing S.A. (part of Menarini Group) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Hypercholesterolemia with a site in United Kingdom — 9 open to participants now, 16 under way, 7 of them phase 3. Hypercholesterolemia · United Kingdom.
Among the 81 studies in Hypercholesterolemia with a site in United Kingdom, this one is the 28th largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2026, is one of 46 in phase 3, reaches primary completion later than 4 of the 15 other live ones, and was the 80th registered.
1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.
Browse Hypercholesterolemia studies →9 of the 81 studies in Hypercholesterolemia with a site in United Kingdom are open now. Recruiting first, the newest first:
LumiraDx UK Limited · Sites in United Kingdom
Ages 16+
AstraZeneca · Sites in United Kingdom, United States, Bulgaria and 8 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 6–11
Verve Therapeutics, Inc. · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6 · Phase 3 47 · Phase 4 2
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 426 is above the median of 109 across 978 interventional studies indexed under Hypercholesterolemia.
Median enrollment 312 across the 72 interventional studies, 847 across the 9 observational. Of the 63 that completed or were terminated, 41 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 81 have an industry lead sponsor. The 10 most frequent:
This study is registered under A. Menarini International Licensing S.A., one of the names counted as Menarini Group. Under that name alone:
This is the only study on the registry with A. Menarini International Licensing S.A. as lead sponsor.
Menarini Group has 2 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
5 of the studies in Hypercholesterolemia with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614958Phase 3A. Menarini International Licensing S.A.Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days | 2027-01 |
| NCT07619131Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | 2027-07-30 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT07351175Anisha WijeyesekeraInvestigating The Potential Of A Hay-Aged Cheese To Reduce Cholesterol As Mediated By Changes In The Gut Microbiome | 2026-12 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 81 studies in Hypercholesterolemia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3, randomized, double-blind, active-controlled study evaluates the efficacy and safety of obicetrapib (OBI) compared to bempedoic acid (BPA) in participants with dyslipidemia at high or very high cardiovascular risk. Participants must have elevated low density lipoprotein cholesterol (LDL-C) levels despite receiving maximally tolerated lipid lowering therapy.
The primary objective is to compare the LDL-C lowering effect of OBI (a CETP inhibitor) against BPA at 12 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females may be enrolled if all 3 of the following criteria are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Obicetrapib 10 mg/Bempedoic Acid Placebo
Drug: Bempedoic Acid 180mg/Placebo Obicetrapib
Orally, Once Daily
Orally, Once Daily
The primary efficacy endpoint is the percentage change from baseline to Day 84 in LDL-C in the OBI group compared to the BPA group.
Time frame: 84 days
Percentage change from baseline to Day 84 in non-HDL-C in the OBI group compared to the BPA group
Time frame: 84 days
Percentage change from baseline to Day 84 in HDL-C in the OBI group compared to the BPA group;
Time frame: 84 days
Percentage change from baseline to Day 84 in ApoA1 in the OBI group compared to the BPA group;
Time frame: 84 days
Percentage change from baseline to Day 84 in Lp(a) in the OBI group compared to the BPA group;
Time frame: 84 days
Percentage change from baseline to Day 84 in ApoB in the OBI group compared to the BPA group;
Time frame: 84 days
Percentage change from baseline to Day 84 in TGs in the OBI group compared to the BPA group.
Time frame: 84 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.
Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 8 months is below that.
Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.